Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Earnings data Q1 2023

Earnings data Q2 2023

Ardelyx

iBio

OPKO Health

4 biotech penny stocks to watch right now. The post 4 Top Penny Stocks To Watch With Big Biotech News This Quarter appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Top Penny Stocks To Watch With Big Biotech News This Quarter

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q4 2022 Earnings Conference Call March 7, 2023 4:30 PM ET Company Participants Ray Furey - EVP, General Counsel and Corporate Secretary. Raul Rodriguez - President and CEO Dave Santos - EVP and Chief Commercial Officer Wolfgang Dummer - EVP and Chief Medical Officer Dean Schorno - EVP and Chief Financial Officer Conference Call Participants Carly Kenselaar - Citi Eun Yang - Jefferies Do Kim - Piper Sandler Kristen Kluska - Cantor Fitzgerald Gary Nachman - BMO Capital Markets Joe Pantginis - H.C.

Rigel Pharmaceuticals, Inc. (RIGL) Q4 2022 Earnings Call Transcript

Rigel (RIGL) delivered earnings and revenue surprises of 114.29% and 36.56%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Rigel Pharmaceuticals (RIGL) Q4 Earnings and Revenues Surpass Estimates

Fourth quarter 2022 Total Revenue of $51.3 million which includes TAVALISSE® net product sales of $21.9 million and REZLIDHIA™ net product sales of $0.9 million REZLIDHIA U.S. commercial launch continues to progress and is supported by recent addition to NCCN Guidelines® for AML Conference call and webcast scheduled today at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif.

Rigel Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif. , Feb. 28, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2022 financial results after market close on Tuesday, March 7, 2023.

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2022 Financial Results and Business Update

˗  REZLIDHIA induced durable remissions in adult patients with mIDH1 R/R AML SOUTH SAN FRANCISCO, Calif. , Feb. 2, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a peer-reviewed publication of data in Blood Advances, which summarizes clinical results from the Phase 2 registrational study of REZLIDHIA™ (olutasidenib), a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1)1, in patients with mIDH1 relapsed or refractory acute myeloid leukemia (R/R AML).

Rigel Announces Publication of REZLIDHIA™ (olutasidenib) Phase 2 Clinical Results in Blood Advances

GlaxoSmithKline

23andMe

These low-priced equities could deliver enormous returns for risk-tolerant shareholders.

3 Penny Stocks That Could Make You Filthy Rich

SOUTH SAN FRANCISCO, Calif. , Jan. 18, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that REZLIDHIA ™ (olutasidenib) has been added by the National Comprehensive Cancer Network® (NCCN®) to the latest NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for acute myeloid leukemia (AML).

National Comprehensive Cancer Network® Adds Newly Approved REZLIDHIA™ (olutasidenib) to Clinical Practice Guidelines in Oncology for Acute Myeloid Leukemia

REZLIDHIA™ U.S. FDA approval and commercial launch for the treatment of adult patients with relapsed or refractory AML with susceptible IDH1 mutation Preliminary fourth quarter 2022 Total Revenue of approximately $51.3 million which includes TAVALISSE® preliminary net product sales of approximately $21.9 million and REZLIDHIA preliminary net product sales of approximately $0.9 million Continued global expansion of TAVALISSE in ITP with Japan PMDA approval for partner Kissei SOUTH SAN FRANCISCO, Calif. , Jan. 9, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today provided a business update including preliminary total revenue for the fourth quarter, ongoing activity from the commercial portfolio, including TAVALISSE® (fostamatinib disodium hexahydrate) tablets and REZLIDHIA™ (olutasidenib) capsules, and upcoming catalysts for 2023.

Rigel Pharmaceuticals Provides Business Update

In terms of product sales, RIGL has been a one drug company with Tavalisse in immune thrombocytopenia. The recent approval of Rezlidhia opens the door for investors to track the growth of another drug, a new source of excitement.

Rigel Pharmaceuticals: A Strong Finish To 2022 And A Potentially Transformative 2023

SOUTH SAN FRANCISCO, Calif. , Dec. 22, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that REZLIDHIA™ (olutasidenib) capsules are available in the U.S. by prescription for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.

Rigel Announces Availability of REZLIDHIA™ (olutasidenib) in the U.S. for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation

R289 is an investigational, oral, inhibitor of interleukin receptor-associated kinases 1 and 4 (IRAK1/4), being studied as a potentially differentiated approach to treating lower-risk MDS SOUTH SAN FRANCISCO, Calif. , Dec. 15, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced it dosed the first patient in its Phase 1b study of R289, an IRAK1/4 dual inhibitor, in patients with lower-risk myelodysplastic syndromes (MDS) who are refractory or resistant to prior therapies.

Rigel Doses First Patient in Phase 1b Study of R289 for the Treatment of Lower-Risk Myelodysplastic Syndromes

ST. LOUIS, Mo.--( BUSINESS WIRE )--Optime Care, a member of the AscellaHealth Family of Companies , today announced a contractual partnership with Rigel Pharmaceuticals, Inc., bringing its full suite patient support/HUB service capabilities to support Rezlidhia™(olutasidenib), a recent FDA-approved treatment for adult patients with relapse or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Optime Care's services for life sciences manufacturers include pre-commercialization and market access expertise, exclusive distribution partnerships, national medication fulfillment and high-touch patient support and HUB services for enhanced patient outcomes.

Optime Care, Specialty Pharmacy Patient Management Organization Announces Enhanced Partnership with Rigel Pharmaceuticals, Inc. for Rezlidhia™ Patients

SOUTH SAN FRANCISCO, Calif. , Dec. 9, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to an employee's entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4).

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Akebia Therapeutics

The Beachbody Co.

ComSovereign Holding

Faraday Future Intelligent Electric

Nymox Pharmaceutical

Sonim Technologies Inc

Statera Biopharma Inc

Tricida Inc

Titan Medical Inc

Penny stocks under $1 to watch this week. The post 10 Top Penny Stocks To Watch Under $1 This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Penny Stocks To Watch Under $1 This Week

eHealth

Eos Energy Enterprises

Vivani Medical Inc

Y-Mabs Therapeutics Inc

Penny stocks to buy according to analysts in December 2022. The post 5 Penny Stocks To Buy According To Analysts, Price Targets Up To 919% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Buy According To Analysts, Price Targets Up To 919%

Penny stocks to buy for under $1 but are they worth the risk? The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 7 Under $1 To Watch Now

Best Penny Stocks To Buy? 4 Under $1 To Watch Now

Ambev

Cosmos Holdings

Use these tips for trading penny stocks right now The post Don't Invest in Penny Stocks Until You've Read This Article appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Don't Invest in Penny Stocks Until You've Read This Article

The FDA approves Rigel's (RIGL) Rezlidhia (olutasidenib) for treating relapsed/refractory acute myeloid leukemia with a susceptible IDH1 mutation. Stock up.

Rigel (RIGL) Up on FDA Nod to Blood Cancer Drug Rezlidhia

Rigel Pharmaceuticals (NASDAQ: RIGL ) stock is heading higher on Friday after getting approval from the U.S. Food and Drug Administration (FDA) for its leukemia treatment. Specifically, the FDA has approved REZLIDHIA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 mutation.

Rigel Pharmaceuticals (RIGL) Stock Soars on FDA Approval News

Shares of Rigel Pharmaceuticals Inc. RIGL, +1.86% soared 39.5% in premarket trading Friday, after the biotechnology company announced Food and Drug Administration approval of its Rezlidhia leukemia treatment. With trading volume of 5.2 million shares, the stock was the most active ahead of the open.

Rigel stock soars after FDA approves leukemia treatment, 2 days after receiving delisting notice

REZLIDHIA is a potentially market-leading, oral, mutant isocitrate dehydrogenase-1 (mIDH1) inhibitor Phase 2 registrational data supporting the approval showed a 35% CR+CRh rate in mIDH1 R/R AML patients with a median duration of response of 25.9 months Conference call and webcast to be held today at 6:30 p.m. ET SOUTH SAN FRANCISCO, Calif.

Rigel Announces U.S. FDA Approval of REZLIDHIA™ (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation

Early clinical data support olutasidenib's potential as a treatment for AML and MDS, in both the relapsed/refractory and newly diagnosed settings Olutasidenib showed durable remission in treatment-naïve and relapsed/refractory AML patients, with or without azacitidine PDUFA target action date is February 15, 2023 SOUTH SAN FRANCISCO, Calif. , Nov. 10, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the publication of data in The Lancet Haematology, which summarizes the Phase 1 results of the Phase 1/2 study of olutasidenib, an investigational, oral, small molecule inhibitor of mutant isocitrate dehydrogenase-1 (mIDH1).

Rigel Announces Publication of Early Clinical Data of Olutasidenib in The Lancet Haematology

Rigel (RIGL) delivered earnings and revenue surprises of 15.38% and 1.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

News for Rigel Pharmaceuticals Stock (RIGL)